Steven Laplante

Steven is a senior biophysical and bioanalytical chemist with +20 years of drug design experience in the pharmaceutical industry. In particular, he is an NMR specialist with extensive applications of X-ray and molecular modeling. He has a proven track record of creating innovative solutions to challenging chemical and biological problems throughout industry and academia.

Currently, Steven's interests are in drug discovery, exposing drug aggregates/nano-entities and exploiting nano-properties for novel discovery strategies. Further interests include: monitoring nano-particles with regards to toxicology, elucidating metabolites, promoting atropisomer chirality, and understanding effects of climate change.

*Steven's accomplishments include: *

• Introducing the guidelines of atropisomer usage in Drug Discovery

• Developing novel strategies that led to discoveries of many drug candidates (HIV, HCV).

• Being the key inventor of advanced drugs for treating hepatitis C infection (Deleobuvir, Faldaprevir and Ciluprevir).

• Developing novel strategies for fragment-, structure- and property-based drug discovery.

• Discovering drug self-assemblies (nano-entities) with important implications for nano-biotechnology.

Education

• Post-doc Ecole polytechnique (1988 — 1990)
• Ph.D. Syracuse University (1983 — 1988)

Companies

• Professor University Quebec INRS Institut Armand Frappier (2015)
• Founder NMX Research and Solutions Inc (2014)
• Consultant and Research Collaborator Harvard Medical School (2014)
• Visiting Scientist Broad Institute (2014)
• Adjunct Professor University of Quebec INRS-IAF (2014 — 2015)
• Senior Research Scientist Boehringer Ingelheim (1991 — 2013)
• CR2 Univ Rene Descartes (1990 — 1991)